(Q38987923)

8 September 2017

title

Quercetin potentiates the antitumor activity of rituximab in diffuse large B-cell lymphoma by inhibiting STAT3 pathway (English)

1 reference

diffuse large B-cell lymphoma

8 September 2017

1 reference

1 reference

1 reference

Xin Li

1

1 reference

8 September 2017

Xinhua Wang

2

1 reference

8 September 2017

Mingzhi Zhang

3

1 reference

8 September 2017

Aimin Li

4

1 reference

8 September 2017

Zhenchang Sun

5

1 reference

8 September 2017

Qi Yu

6

1 reference

8 September 2017

publication date

1 November 2014

1 reference

Cell Biochemistry and Biophysics

8 September 2017

published in

1 reference

8 September 2017

volume

70

1 reference

8 September 2017

issue

2

1 reference

8 September 2017

page(s)

1357-1362

1 reference

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Quercetin and cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

The flavonoid quercetin in disease prevention and therapy: facts and fancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

STATs and gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

How cells respond to interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

The STATs of cancer--new molecular targets come of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

STATs in cancer inflammation and immunity: a leading role for STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Blockade of oxidized LDL-triggered endothelial apoptosis by quercetin and rutin through differential signaling pathways involving JAK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0064-8

10.1007/S12013-014-0064-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

8 September 2017

1026160596

0 references

1 reference